Cargando…

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cha, Yoon Jin, Kim, Dooreh, Bae, Soong June, Ahn, Sung Gwe, Jeong, Joon, Lee, Hye Sun, Jeon, Soyoung, Yoo, Tae-Kyung, Park, Woo-Chan, Yoon, Chang Ik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486819/ https://www.ncbi.nlm.nih.gov/pubmed/34599199 http://dx.doi.org/10.1038/s41598-021-97250-2

Ejemplares similares

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
por: Lee, Seung Eun, et al.
Publicado: (2020)

SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3
por: Pang, Jia-Min B., et al.
Publicado: (2021)

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
por: Kim, Taehee, et al.
Publicado: (2020)

Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery With Sentinel Lymph Node Biopsy: Pooled Analysis Using Data From a Systematic Review and Two Institutions
por: Yoon, Chang Ik, et al.
Publicado: (2020)

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022)

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients
por: Li, Wenbin, et al.
Publicado: (2018)

(18)F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
por: Kim, Hyun Jeong, et al.
Publicado: (2022)

CT‐guided transthoracic needle biopsy for evaluation of PD‐L1 expression: Comparison of 22C3 and SP263 assays
por: Beck, Kyongmin S., et al.
Publicado: (2019)

High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
por: Kim, Sue Youn, et al.
Publicado: (2022)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
por: Park, Soeun, et al.
Publicado: (2021)

The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
por: Yoon, Chang-Ik, et al.
Publicado: (2021)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
por: Yoon, Chang Ik, et al.
Publicado: (2020)

Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma
por: García, Alejandro, et al.
Publicado: (2020)

Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction
por: Park, Soeun, et al.
Publicado: (2020)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
por: Smith, Jacquelyn, et al.
Publicado: (2016)

PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
por: Park, Yujun, et al.
Publicado: (2020)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
por: Compérat, Eva, et al.
Publicado: (2021)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays
por: Evans, Harriet, et al.
Publicado: (2022)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
por: Xu, Haipeng, et al.
Publicado: (2017)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
por: He, Jiankun, et al.
Publicado: (2023)

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Bae, Soong June, et al.
Publicado: (2022)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)
por: Ma, Jing, et al.
Publicado: (2018)

Comments on the Article by Miura et al.: “Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests”
por: Yatabe, Yasushi
Publicado: (2023)

Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery
por: Yoon, Chang Ik, et al.
Publicado: (2023)

Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
por: Lee, Yangkyu, et al.
Publicado: (2022)

PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263
por: Munari, Enrico, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qb379n5aijftvm1miu6pfgf8i9